ERAS
Price
$10.59
Change
+$8.14 (+332.24%)
Updated
Feb 3 closing price
Capitalization
3.28B
43 days until earnings call
Intraday BUY SELL Signals
IPSC
Price
$1.84
Change
+$1.24 (+206.67%)
Updated
Feb 3 closing price
Capitalization
160.83M
36 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs IPSC

Header iconERAS vs IPSC Comparison
Open Charts ERAS vs IPSCBanner chart's image
Erasca
Price$10.59
Change+$8.14 (+332.24%)
Volume$5.67M
Capitalization3.28B
Century Therapeutics
Price$1.84
Change+$1.24 (+206.67%)
Volume$1.74M
Capitalization160.83M
ERAS vs IPSC Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
IPSC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. IPSC commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and IPSC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ERAS: $10.59 vs. IPSC: $1.84)
Brand notoriety: ERAS and IPSC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 94% vs. IPSC: 82%
Market capitalization -- ERAS: $3.28B vs. IPSC: $160.83M
ERAS [@Biotechnology] is valued at $3.28B. IPSC’s [@Biotechnology] market capitalization is $160.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileIPSC’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • IPSC’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than IPSC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while IPSC’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • IPSC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both ERAS and IPSC are a bad buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а +0.81% price change this week, while IPSC (@Biotechnology) price change was -30.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

IPSC is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.28B) has a higher market cap than IPSC($161M). ERAS YTD gains are higher at: 184.543 vs. IPSC (84.962). IPSC has higher annual earnings (EBITDA): -909K vs. ERAS (-131.32M). ERAS has more cash in the bank: 288M vs. IPSC (133M). IPSC has less debt than ERAS: IPSC (45M) vs ERAS (48.3M). IPSC has higher revenues than ERAS: IPSC (113M) vs ERAS (0).
ERASIPSCERAS / IPSC
Capitalization3.28B161M2,035%
EBITDA-131.32M-909K14,446%
Gain YTD184.54384.962217%
P/E RatioN/AN/A-
Revenue0113M-
Total Cash288M133M217%
Total Debt48.3M45M107%
TECHNICAL ANALYSIS
Technical Analysis
ERASIPSC
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
IPSC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RVCB24.50N/A
N/A
River Valley Community Bancorp
ESYJY6.75-0.01
-0.15%
easyJet Plc
ORLCF0.04N/A
-1.88%
ORACLE COMMODITY HLDG CORP
AMADF63.71-2.90
-4.36%
Amadeus IT Group SA
GRCLF4.07-0.76
-15.67%
GrainCorp Ltd.

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.24%
RVMD - ERAS
57%
Loosely correlated
-1.22%
IRON - ERAS
50%
Loosely correlated
-1.17%
IDYA - ERAS
48%
Loosely correlated
+0.50%
ACLX - ERAS
48%
Loosely correlated
-0.01%
NRIX - ERAS
48%
Loosely correlated
-1.76%
More

IPSC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IPSC has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IPSC jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPSC
1D Price
Change %
IPSC100%
N/A
CRSP - IPSC
54%
Loosely correlated
+1.34%
FATE - IPSC
50%
Loosely correlated
-5.69%
CABA - IPSC
49%
Loosely correlated
+3.60%
NTLA - IPSC
48%
Loosely correlated
-0.08%
KYTX - IPSC
47%
Loosely correlated
N/A
More